Barclays Raises PT on Hims & Hers Health (HIMS) Stock [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
On March 11, Barclays analyst Glen Santangelo lifted its price objective on the company's stock to $29 from $25, while keeping an “Overweight” rating. The analyst highlighted that a strong increase in share price after the Novo Nordisk agreement reflects a significant market opportunity. Barclays Raises PT on Hims & Hers Health (HIMS) Stock Additionally, it also demonstrates the removal of legal overhang for Hims & Hers Health, Inc. (NYSE:HIMS)'s stock. As per the firm, the broader market has been underappreciating the company's opportunity from new products. Notably, in a different release, Hims & Hers Health, Inc. (NYSE:HIMS) announced a collaboration with Novo Nordisk as part of a new strategy for weight loss care treatments involving GLP-1s. In the US, the company aims to offer GLP-1 customers access to a broad assortment of medications that are FDA-approved, and provide compounded semaglutide via the platform on a limited scale. Hims & Hers Health, Inc. (NYSE:HIMS) is a c
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- When generic versions of weight-loss drugs arrive, public plans should cover them, experts say [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- FDA: Novo Nordisk failed to report deaths of weight-loss drug patients [USA TODAY]USA TODAY
- Novo Nordisk Patent Loss In India Tests GLP 1 Valuation Story [Yahoo! Finance]Yahoo! Finance
- Eli Lilly Just Opened the Door to Even Greater GLP-1 Growth [Yahoo! Finance]Yahoo! Finance
- Why the Novo Nordisk and Hims & Hers Deal Is a Win for Both Stocks [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 3/9/26 - Form 6-K
- 3/2/26 - Form 6-K
- 3/2/26 - Form 6-K
- NVO's page on the SEC website